Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02008890
Recruitment Status : Completed
First Posted : December 11, 2013
Results First Posted : January 4, 2019
Last Update Posted : January 4, 2019
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a total of 148 weeks

Condition or disease Intervention/treatment Phase
Palmoplantar Pustular Psoriasis Biological: Secukinumab 300mg Biological: Secukinumab 150mg Biological: Placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 237 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab to Demonstrate Efficacy as Assessed by Palmoplantar Pustulosis Psoriasis Area and Severity Index (ppPASI) at 16 Weeks of Treatment, Compared to Placebo, and to Assess Long-term Safety, Tolerability, and Efficacy in Subjects With Moderate to Severe Chronic Palmoplantar Pustular Psoriasis - Amended With an Optional Extension Treatment Period of up to a Total of 148 Weeks
Actual Study Start Date : December 26, 2013
Actual Primary Completion Date : November 24, 2014
Actual Study Completion Date : May 31, 2017


Arm Intervention/treatment
Experimental: Secukinumab 300mg

Secukinumab 300mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.

In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.

For extension period: Secukinumab 300mg at 4-weekly intervals starting Week 52 up to Week 148.

Biological: Secukinumab 300mg
Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered

Biological: Placebo
secukinumab placebo s.c. (two PFS injections of placebo) self-administered

Experimental: Secukinumab 150mg

Secukinumab 150mg once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 48.

In order to maintain the blinding beyond the primary endpoint, placebo was administered at Weeks 17, 18 and 19.

For extension period: Secukinumab 150mg at 4-weekly intervals starting Week 52 up to Week 148.

Biological: Secukinumab 150mg
secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered

Biological: Placebo
secukinumab placebo s.c. (two PFS injections of placebo) self-administered

Placebo Comparator: Placebo
Placebo once weekly at Weeks 1, 2 and 3, thereafter at 4-weekly intervals starting Week 4 until Week 12. Patients who achieved ppPASI 75 at Week 16 remained on placebo treatment Until week 48 and were not eligible to enter the extension. Patients who did not achieve ppPASI 75 at Week 16 were re-randomized to receive Secukinumab 150mg or Secukinumab 300mg from Week 16 onwards up to Week 148.
Biological: Secukinumab 300mg
Secukinumab was used as 150 mg pre-filled syringes (PFS) in a double-blinded fashion. Secukinumab 300 mg s.c. (two PFS injections of the 150 mg dose) self-administered

Biological: Secukinumab 150mg
secukinumab 150 mg s.c. (one PFS injection of the 150 mg dose + one PFS injection of placebo) self-administered

Biological: Placebo
secukinumab placebo s.c. (two PFS injections of placebo) self-administered




Primary Outcome Measures :
  1. Percentage of Participants With ppPASI 75 Response at Week 16 (Period 1) [ Time Frame: Baseline to Week 16 ]
    The primary endpoint was assessed by the palmoplantar pustulosis Psoriasis Area and Severity Index 75 (ppPASI 75). The percentage of subjects who achieved a 75% reduction in ppPASI score from Baseline to Week 16 was measured. The ppPASI is a modification of the PASI score and adjusted for palmoplantar pustular psoriasis by classifying and scoring erythema, scaling (desquamation) and pustules/vesicles. Both palms and both plants are scored from 0 to 4. The extent of involvement of each region of the body is scored from 0 to 6. The total ppPASI score can range from a lower level of 0, corresponding to no signs of psoriasis, up to a maximum of 72.


Secondary Outcome Measures :
  1. ppPASI: Absolute Change From Baseline to Week 16 [ Time Frame: Baseline to Week 16 ]
    A secondary endpoint was assessed by the palmoplantar pustulosis Psoriasis Area and Severity Index (ppPASI). The mean change of ppPASI score from Baseline to Week 16 was measured. The ppPASI is a modification of the PASI score and adjusted for palmoplantar pustular psoriasis by classifying and scoring erythema, scaling (desquamation) and pustules/vesicles. Both palms and both plants are scored from 0 to 4. The extent of involvement of each region is scored from 0 to 6. The total ppPASI score can range from a lower level of 0, corresponding to no signs of psoriasis, up to a maximum of 72.

  2. Percentage of Participants With ppPASI 75 Response Over Time (Period 1) [ Time Frame: Baseline to Week 16 ]
    A secondary endpoint was assessed as response rate of patients to treatment measured by the palmoplantar pustulosis Psoriasis Area and Severity Index 75 (ppPASI 75). The percentage of subjects who achieve a 75% reduction in ppPASI score from Baseline to each post-baseline visit is measured. The ppPASI is a modification of the PASI score and adjusted for palmoplantar pustular psoriasis by classifying and scoring erythema, scaling (desquamation) and pustules/vesicles. Both palms and both plants are scored from 0 to 4. The extent of involvement of each region of the body is scored from 0 to 6. The total ppPASI score can range from a lower level of 0, corresponding to no signs of psoriasis, up to a maximum of 72.

  3. Percentage of Participants With ppPASI 75 Response Over Time (Period 2) [ Time Frame: Week 16 to Week 52 ]
    A secondary endpoint was assessed as response rate of patients to treatment measured by the palmoplantar pustulosis Psoriasis Area and Severity Index 75 (ppPASI 75). The percentage of subjects who achieve a 75% reduction in ppPASI score from Baseline to each post-baseline visit is measured. The ppPASI is a modification of the PASI score and adjusted for palmoplantar pustular psoriasis by classifying and scoring erythema, scaling (desquamation) and pustules/vesicles. Both palms and both plants are scored from 0 to 4. The extent of involvement of each region of the body is scored from 0 to 6. The total ppPASI score can range from a lower level of 0, corresponding to no signs of psoriasis, up to a maximum of 72.

  4. Percentage of Participants With ppPASI 75 Response Over Time (Extension Period) [ Time Frame: Week 52 to Week 148 ]
    A secondary endpoint was assessed as response rate of patients to treatment measured by the palmoplantar pustulosis Psoriasis Area and Severity Index 75 (ppPASI 75). The percentage of subjects who achieved a 75% reduction in ppPASI score from Baseline to each post-baseline visit was measured. The ppPASI is a modification of the PASI score and adjusted for palmoplantar pustular psoriasis by classifying and scoring erythema, scaling (desquamation) and pustules/vesicles. Both palms and both plants are scored from 0 to 4. The extent of involvement of each region of the body is scored from 0 to 6. The total ppPASI score can range from a lower level of 0, corresponding to no signs of psoriasis, up to a maximum of 72.

  5. Percentage of Participants With Most Frequent Adverse Events - Period 1 (Patient's Safety) [ Time Frame: Baseline to Week 16 (Period 1) ]
    Most frequent (at least 5% in any of the AIN457 groups) Adverse Events

  6. Percentage of Participants With Most Frequent Adverse Events - Period 2 (Patient's Safety) [ Time Frame: Week 16 to Week 52 (Period 2) ]
    Most frequent (at least 5% in any of the AIN457 groups) Adverse Events

  7. Percentage of Participants With Most Frequent Adverse Events - Extension Period (Patient's Safety) [ Time Frame: Week 52 to Week 148 (extension period) ]
    Most frequent (at least 5% in any of the AIN457 groups) Adverse Events



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Palmoplantar pustular psoriasis for at least 6 months before Randomization
  • Moderate to severe palmoplantar pustular psoriasis as defined at Baseline by:

    • ppPASI score of ≥ 12 and
    • DLQI ≥ 10
  • Candidate for systemic therapy, defined as having palmoplantar pustular psoriasis inadequately controlled by:

    • Topical treatment, and/or
    • Phototherapy, and/or
    • Previous systemic therapy

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque psoriasis and pustular palmoplantar psoriasis (e.g., erythrodermic, guttate, or generalized pustular psoriasis)
  • Drug-induced psoriasis (e.g., new onset or current exacerbation from beta-blockers, calcium channel inhibitors, or lithium) or history of proven contact dermatitis
  • Patients not willing to limit UV light exposure (e.g. sunbathing and/or the use of tanning devices) during the course of the study
  • Ongoing use of prohibited psoriasis treatments (e.g., topical or systemic corticosteroids, UV therapy). Washout periods detailed in the protocol have to be adhered to
  • Previous exposure to any biologic drug directly targeting IL-17 or IL-17 Receptor (e.g., secukinumab, ixekizumab, or brodalumab)
  • Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using effective methods of contraception during dosing of study treatment and for 16 weeks after stopping treatment
  • Active ongoing inflammatory diseases other than psoriasis that might confound the evaluation of the benefit of secukinumab therapy
  • Use of any other investigational drugs within 4 weeks of study drug initiation or within a period of 5 half-lives of the investigational treatment, whichever is longer

Other protocol-defined inclusion/exclusion criteria may apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02008890


  Hide Study Locations
Locations
Layout table for location information
Austria
Novartis Investigative Site
Feldkirch, Austria, A-6807
Novartis Investigative Site
Graz, Austria, 8036
Novartis Investigative Site
Linz, Austria, A-4020
Novartis Investigative Site
Wien, Austria, 1090
Novartis Investigative Site
Wien, Austria, A-1090
Belgium
Novartis Investigative Site
Bruxelles, Belgium, 1200
Novartis Investigative Site
Gent, Belgium, 9000
Novartis Investigative Site
Leuven, Belgium, 3000
Novartis Investigative Site
Liege, Belgium, 4000
France
Novartis Investigative Site
Limoges cedex, Haute Vienne, France, 87000
Novartis Investigative Site
Bordeaux Cedex, France, 33075
Novartis Investigative Site
Clermont Ferrand cedex 1, France, 63003
Novartis Investigative Site
Martigues, France, 13500
Novartis Investigative Site
Nice Cedex 3, France, 06202
Novartis Investigative Site
Paris, France, 75010
Novartis Investigative Site
Paris, France, 75014
Novartis Investigative Site
Poitiers, France, 86021
Novartis Investigative Site
Rouen, France, 76031
Novartis Investigative Site
Toulouse Cedex, France, 31400
Germany
Novartis Investigative Site
Berlin, Germany, 10827
Novartis Investigative Site
Bochum, Germany, 44803
Novartis Investigative Site
Dresden, Germany, 01307
Novartis Investigative Site
Duesseldorf, Germany, D 40225
Novartis Investigative Site
Freiburg, Germany, 79104
Novartis Investigative Site
Gera, Germany, 07548
Novartis Investigative Site
Gottingen, Germany, 37075
Novartis Investigative Site
Greifswald, Germany, 17475
Novartis Investigative Site
Hamburg, Germany, 20354
Novartis Investigative Site
Hamburg, Germany, 22391
Novartis Investigative Site
Hanau, Germany, 63450
Novartis Investigative Site
Kiel, Germany, 24105
Novartis Investigative Site
Lubeck, Germany, 23538
Novartis Investigative Site
Mahlow, Germany, 15831
Novartis Investigative Site
Muenster, Germany, 48149
Novartis Investigative Site
Plauen, Germany, 08529
Novartis Investigative Site
Recklinghausen, Germany, 45657
Novartis Investigative Site
Schwerin, Germany, 19055
Italy
Novartis Investigative Site
Bologna, BO, Italy, 40138
Novartis Investigative Site
Brescia, BS, Italy, 25123
Poland
Novartis Investigative Site
Bydgoszcz, Poland, 85-094
Novartis Investigative Site
Gdansk, Poland, 80-803
Novartis Investigative Site
Olsztyn, Poland, 10-045
Novartis Investigative Site
Zabrze, Poland, 41-800
Russian Federation
Novartis Investigative Site
Moscow, Russian Federation, 107076
Novartis Investigative Site
Rostov on Don region, Russian Federation, 346880
Novartis Investigative Site
Ryazan, Russian Federation, 390046
Novartis Investigative Site
Saratov, Russian Federation, 410012
Spain
Novartis Investigative Site
Valencia, Comunidad Valenciana, Spain, 46014
Novartis Investigative Site
La Laguna, Santa Cruz De Tenerife, Spain, 38320
Novartis Investigative Site
A Coruna, Spain, 15001
Novartis Investigative Site
Barcelona, Spain, 08041
Novartis Investigative Site
Madrid, Spain, 28006
Novartis Investigative Site
Madrid, Spain, 28031
Sweden
Novartis Investigative Site
Göteborg, Vastra Gotalands Lan, Sweden, SE-413 45
Novartis Investigative Site
Joenkoeping, Sweden, 551 85
Novartis Investigative Site
Malmo, Sweden, SE-205 02
Novartis Investigative Site
Stockholm, Sweden, 171 76
Novartis Investigative Site
Uppsala, Sweden, 751 85
United Kingdom
Novartis Investigative Site
Leytonstone, London, United Kingdom, E11 1NR
Novartis Investigative Site
Salford, Manchester, United Kingdom, M6 8HD
Novartis Investigative Site
Dundee, Perthshire, United Kingdom, DD1 9SY
Novartis Investigative Site
Dudley, West Midlands, United Kingdom, DY1 2HQ
Novartis Investigative Site
Glasgow, United Kingdom, G11 6NT
Novartis Investigative Site
Liverpool, United Kingdom, L14 3PE
Novartis Investigative Site
Newport, United Kingdom, NP20 4SZ
Novartis Investigative Site
Portsmouth, United Kingdom, PO6 6AD
Novartis Investigative Site
Wolverhampton, United Kingdom, WV10 0QP
Novartis Investigative Site
York, United Kingdom, YO31 8HE
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals

Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02008890     History of Changes
Other Study ID Numbers: CAIN457A3301
2013-003086-34 ( EudraCT Number )
First Posted: December 11, 2013    Key Record Dates
Results First Posted: January 4, 2019
Last Update Posted: January 4, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description:

Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Keywords provided by Novartis ( Novartis Pharmaceuticals ):
palmoplantar, pustular, psoriasis
Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs